Phase II Trial of Temsirolimus (CCI-779) in Recurrent Glioblastoma Multiforme: A North Central Cancer Treatment Group Study

Evanthia Galanis, Daniel J. Walsh|Journal of Clinical Oncology|2005

Cited by 695